12.41
-0.36(-2.82%)
Currency In USD
| Previous Close | 12.77 |
| Open | 12.76 |
| Day High | 12.99 |
| Day Low | 12.2 |
| 52-Week High | 29.3 |
| 52-Week Low | 12.04 |
| Volume | 899,230 |
| Average Volume | 1.05M |
| Market Cap | 1.13B |
| PE | -9.7 |
| EPS | -1.28 |
| Moving Average 50 Days | 14.14 |
| Moving Average 200 Days | 21.66 |
| Change | -0.36 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $362.23 as of February 05, 2025 at a share price of $12.41. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $420.25 as of February 05, 2025 at a share price of $12.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
GlobeNewswire Inc.
Jan 29, 2025 1:30 PM GMT
Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
GlobeNewswire Inc.
Jan 23, 2025 1:30 PM GMT
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about reproductive and prenatal g
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
GlobeNewswire Inc.
Jan 21, 2025 1:30 PM GMT
Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a